MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14796694.2025.2497749

Медицинская библиотека · Future oncology (London, England) · 2025

Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC.

Veccia Antonello, Basso Umberto, Cattrini Carlo, Ermacora Paola, Maruzzo Marco, Alberti Martina, Anesi Cecilia, Bimbatti Davide, Cani Massimiliano, Crespi Veronica, Farinea Giovanni, Kadrija Dzenete, Kinspergher Stefania, Lai Eleonora, Lay Ludovica, Maines Francesca, Mennitto Alessia, Pierantoni Francesco, Samuelly Alessandro, Urban Susanna, Caffo Orazio, Buttigliero Consuelo

СтатьяПеревод в очереди

Аннотация

AIM: Androgen receptor signaling inhibitors (ARSI) demonstrated to be efficacious as first-line therapy for mCRPC. The present real-world study aimed to identify the characteristics of the long-term responders (LTR) patients to first-line ARSI.

METHODS

We retrospectively reviewed a consecutive series of 622 mCRPC patients treated with one ARSI as first line. Patients received standard doses of abiraterone (1000 mg daily plus prednisone 10 mg daily) or enzalutamide (160 mg daily) until progression. Patients with an ARSI exposure ≥ 36 months were considered as LTR.

RESULTS

We identified 99 LTR patients who were compared to 523 no-LTR patients. At the multivariable analysis, LTR patients showed younger age (p < 0.0001), longer time to mCRPC (p < 0.0001), higher baseline levels of hemoglobin (p = 0.007), lower baseline PSA levels (p = 0.03), longer PSA doubling time (p = 0.03), low number of bone metastases (p = 0.01), and receivedenzalutamide (p = 0.01). The median overall survival (OS) of LTR was 78.2 months (95% CI 72.3-84.1 months) vs 27.7 months of no-LTR (95% CI 25.9-29.6 months).

CONCLUSIONS

Several clinical and biological factors allow to identify those patients with higher probability of becoming LTR to ARSI in first-line mCRPC setting.

Для цитирования: Veccia Antonello, Basso Umberto, Cattrini Carlo, Ermacora Paola, Maruzzo Marco, Alberti Martina, Anesi Cecilia, Bimbatti Davide, Cani Massimiliano, Crespi Veronica, Farinea Giovanni, Kadrija Dzenete, Kinspergher Stefania, Lai Eleonora, Lay Ludovica, Maines Francesca, Mennitto Alessia, Pierantoni Francesco, Samuelly Alessandro, Urban Susanna, Caffo Orazio, Buttigliero Consuelo. Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC.. Future oncology (London, England). 2025. DOI: 10.1080/14796694.2025.2497749.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.